Six Recurrent Amyloid-Related Imaging Abnormality Episodes in a Patient Treated With Aducanumab

JAMA Neurol. 2022 Jan 1;79(1):87-89. doi: 10.1001/jamaneurol.2021.3933.

Authors

Jacob N Hall¹, Elizabeth Mormino², Amanda Ng², Athanasia Boumis³, Jennifer L Gaudioso⁴, Guido A Davidzon⁵, Sharon J Sha²

Affiliations

¹ The Neurology Center of Southern California, Temecula.
² Department of Neurology and Neurological Sciences, Stanford University, Stanford, California.
³ Stanford Center for Clinical Research, Stanford University, Stanford, California.
⁴ Global Alzheimer's Platform Foundation, San Francisco, California.
⁵ Division of Nuclear Medicine & Molecular Imaging, Department of Radiology, Stanford University, Stanford, California.

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Amyloid / metabolism*
Antibodies, Monoclonal, Humanized / adverse effects*
Brain / diagnostic imaging
Brain / drug effects*
Brain / metabolism
Brain / pathology*
Humans
Magnetic Resonance Imaging
Male

Substances

Amyloid
Antibodies, Monoclonal, Humanized
aducanumab

Grants and funding

P30 AG066515/AG/NIA NIH HHS/United States